We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| DexCom Inc | NASDAQ:DXCM | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.72 | 1.36% | 128.37 | 85.00 | 141.77 | 129.22 | 126.76 | 127.22 | 1,803,582 | 05:00:08 |
From May 2022 to May 2024
By Kathryn Hardison
Shares of DexCom Inc. increased 4.3% to $122.99 on Thursday following clearance from the Food and Drug Administration for its next-generation continuous glucose monitoring system.
The shares reached an intraday high of $125.55, a level last seen April 21 when they traded at $125.95, according to FactSet. The shares are 8.4% lower for the year.
DexCom said the FDA cleared its G7 continuous glucose monitoring system for people aged two years and older with all types of diabetes. The system is wearable and doesn't require fingersticks or scanning, the company said.
Chief Executive Kevin Sayer said the system will become commercially available in the coming months.
Write to Kathryn Hardison at kathryn.hardison@wsj.com
(END) Dow Jones Newswires
December 08, 2022 13:29 ET (18:29 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year DexCom Chart |
1 Month DexCom Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
